

# **Biocompatible hypocrellin A-Fe(III) nanoparticles exhibiting efficient photo-activated CDT *in vitro* and *in vivo***


Zhanhua Wang,<sup>a,b</sup> Chuan Gao,<sup>c</sup> Xuwen Da,<sup>a,b</sup> Yao Jian,<sup>a,b</sup> Chao Zhang,<sup>a,b</sup> Yishan Yao,\*<sup>c</sup> Xuesong Wang,\*<sup>a,b</sup> Qianxiong Zhou\*<sup>a</sup>

\*Corresponding authors


<sup>a</sup> Key Laboratory of Photochemical Conversion and Optoelectronic Materials, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, P. R. China. E-mail: xswang@mail.ipc.ac.cn (X. S. Wang), zhouchianxiong@mail.ipc.ac.cn (Q. X. Zhou); Fax: +86-10-62564049; Tel: +86-10-82543592

<sup>b</sup> University of Chinese Academy of Sciences, Beijing 100049, P. R. China


<sup>c</sup> Beijing Institute of Pharmacology and Toxicology, Beijing 100850, P. R. China. E-mail: spray\_yao123456@hotmail.com (Y. S. Yao)




**Fig. S1** (a) UV-vis absorption spectral changes of HA-Fe(III) NPs (20  $\mu\text{g}/\text{mL}$ ) in  $\text{H}_2\text{O}$  (containing 1% DMSO) over 48 h in the dark. (b) UV-vis absorption spectra of HA-Fe(III) NPs (the mother solution (5 mg/mL in DMSO) was diluted into 20  $\mu\text{g}/\text{mL}$  in  $\text{H}_2\text{O}$ ) before and after 48 h.




**Fig. S2** (a) Absorption spectral changes of HA (25  $\mu\text{M}$ ) in ethanol upon addition of  $\text{FeCl}_3$  ( $\mu\text{M}$ ); (b) mole ratio plot for  $\text{Fe}^{3+}$ -HA in ethanol obtained by plotting the absorbance at 625 nm as a function of the mole ratio of  $\text{Fe}^{3+}$  to HA.




**Fig.S3** Degradation of ABDA in the presence of HA-Fe(III) NPs (10  $\mu\text{g}/\text{mL}$ ) upon 600 nm irradiation (22.5  $\text{mW}/\text{cm}^2$ ) with different times.




**Fig S4** EPR spectra of HA (0.2 mM) (a) or HA-Fe(III) NPs (with the same absorbance as HA at 600 nm) (b) in air-saturated DMSO (containing 20 mM TEMP) in the dark or upon irradiation (600 nm, 22.5  $\text{mW cm}^{-2}$ ).




**Fig.S5** Photoinduced  $\cdot\text{OH}$  generation ability of HA and HA-Fe(III) NPs (the absorbance at 600 nm was adjusted to the same as that of HA) using HPF (10  $\mu\text{M}$ ) as a  $\cdot\text{OH}$  fluorescence probe in PBS. (a) HA + Dark; (b) HA + Light (600 nm LED, 22.5  $\text{mW cm}^{-2}$ ); (c) HA-Fe(III) NPs + Dark; (d) HA-Fe(III) NPs + Light (600 LED, 22.5  $\text{mW cm}^{-2}$ ). The fluorescence spectra were recorded using excitation wavelength of 490 nm.




**Fig. S6** EPR spectra of HA (0.3 mM) (a) or HA-Fe(III) NPs (with the same absorbance as HA at 600 nm) (b) in air-saturated PBS (containing 20 mM DMPO) in the dark or upon irradiation (600 nm, 22.5  $\text{mW cm}^{-2}$ ).




**Fig. S7** UV-vis spectral changes of Rhodamine B (RhB) under different conditions. (a) HA-Fe(III) NPs (25  $\mu\text{g}/\text{mL}$ ) + RhB (40  $\mu\text{M}$ ) +  $\text{H}_2\text{O}_2$  (8.8 mM) + dark; (b) HA-Fe(III) NPs (25  $\mu\text{g}/\text{mL}$ ) + RhB (40  $\mu\text{M}$ ) +  $\text{H}_2\text{O}_2$  (8.8 mM) + Light (600 nm, 22.5  $\text{mW}/\text{cm}^2$ ).




**Fig. S8** Confocal fluorescence images of A549 intracellular ROS levels. Cells were treated with HA (0.14  $\mu\text{M}$ ) under normoxia (21%  $\text{O}_2$ ) or hypoxia (3%  $\text{O}_2$ ). The light groups were irradiated by 600 nm LED for 30 min (22.5  $\text{mW cm}^{-2}$ ). DCFH-DA was used as the ROS probe. Scale bars: 50  $\mu\text{m}$ .




**Fig. S9** Cell viability of cisplatin-resistant A549 cells treated by HA-Fe(III) NPs or HA in the dark or under light irradiation for 30 min (600 nm, 22.5 mW cm $^{-2}$ ).




**Fig. S10** Cell viability of SKOV-3 cells incubated with HA-Fe(III) NPs or HA in the dark or under light irradiation for 30 min (600 nm, 22.5 mW cm $^{-2}$ ).




**Fig. S11** Cell viability of A549 cells incubated with HA-Fe(III) NPs or HA in the dark or under light irradiation for 30 min (600 nm, 22.5 mW  $\text{cm}^{-2}$ ).




**Fig. S12** Cell viability of A549 cells (in hypoxia, 3%  $\text{O}_2$ ) incubated with HA-Fe(III) NPs or HA in the dark or under light irradiation for 30 min (600 nm, 22.5 mW  $\text{cm}^{-2}$ ).



**Fig. S13** Cytotoxicity of cisplatin towards A549 (left), cis-A549 (middle) and SKOV3 cells (right).



**Fig. S14** Cell viability of ISOE80 cells incubated with HA-Fe(III) NPs in the dark or under light irradiation for 30 min (600 nm, 22.5  $\text{mW cm}^{-2}$ ).



**Fig. S15** Histological analysis of the organs acquired from the mice bearing 4T1 tumors on the 14th day after various treatments. Scale bars: 200  $\mu\text{m}$ .